PATENT CLAIM ANALYSIS

Application Number: 16343271
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-08
Patent Classification: ["546", "153000"]

Abstract:
The present application provides a quinolyl-substituted carboxylic acid compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, as well as a method for preparing the compound, a use of the compound, and a formulation containing the quinolyl-substituted carboxylic acid compound or the pharmaceutically acceptable salt thereof. This type of compounds are inhibitors for AXL and/or VEGFR2 protein kinase, and can be used to treat diseases caused by abnormality of the two protein kinases, such as, tumor, etc.;

Claim (Index 9):
A preparation method of the quinolyl-substituted carboxylic acid compound or the pharmaceutically acceptable salt thereof according to  claim 1 , comprising, but not limited to, the following steps: wherein V 1 , V 2 , R, L and M are as defined in  claim 1 ; LG is F, Cl, Br, I, CH 3 SO 3 , CH 3 CH 2 SO 3 , CH 3 (CH 2 ) 2 SO 3 , (CH 3 ) 2 CHSO 3 , tert-BuSO 3 , PhSO 3 , o-CH 3 PhSO 3 , m-CH 3 PhSO 3 , p-CH 3 PhSO 3 , o-O 2 NPhSO 3 , m-O 2 NPhSO 3 , p-O 2 NPhSO 3 , or CF 3 SO 3 ; and RR is hydrogens C 1-12  alkyl, C 3-12  cycloalkyl, C 6-12  aryl, C 5-12  heteroaryl or C 3-12  heteroalicyclic group, and hydrogen of RR is selectively substituted by G 4 ; wherein G 4  is selected from hydrogen, deuterium, \u2014CN, \u2014CF 3 , \u2014CO 2 H, halogen, C 1-12  alkyl, C 3-12  cycloalkyl, C 2-12  alkenyl, C 2-12  alkynyl, C 6-12  aryl, C 5-12  heteroaryl, C 3-12  heteroalicyclic group, R 1 O\u2014, R 1 R 2 N\u2014, R 1 S(\u2550O) m \u2014, R 1 R 2 NS(\u2550O) m \u2014, R 3 C(\u2550O)\u2014, R 1 R 2 NC(\u2550O)\u2014, R 1 OC(\u2550O)\u2014, R 3 C(\u2550O)O\u2014, R 1 R 2 NC(\u2550O)\u2014, R 3 C(\u2550O)NR 1 \u2014, R 1 R 2 NC(\u2550O)NR 4 \u2014, R 1 OC(\u2550O)NR 4 \u2014, R 1 S(\u2550O) m NR 4 \u2014, R 1 R 2 NS(\u2550O) m NR 4 \u2014, R 1 R 2 NC(\u2550NR 5 )NR 4 \u2014, R 1 R 2 NC(\u2550CHNO 2 )NR 4 \u2014, R 1 R 2 NC(\u2550N\u2014CN)NR 4 \u2014, R 1 R 2 NC(\u2550NR 5 )\u2014, R 1 S(\u2550O)(\u2550NR 5 )NR 4 \u2014, and R 1 R 2 NS(\u2550O)(\u2550NR 5 )\u2014; R 1 , R 2 , R 3 , R 4  and R 5  are each independently selected from hydrogen, deuterium, C 1-12  alkyl, C 2-12  alkenyl, C 2-12  alkynyl, C 3-12  cycloalkyl, C 6-12  aryl, C 5-12  heteroaryl, and C 3-12  heteroalicyclic group; R 1  and R 2 , when being bonded to a same nitrogen atom, form a C 3-12  heteroalicyclic ring together with the nitrogen atom, wherein the C 3-12  heteroalicyclic ring selectively contains a hetero atom of O, N, and S(\u2550O) m ; and hydrogen of R 1 , R 2 , R 3 , R 4  and R 5  is selectively substituted by halogen, CN, C 1-12  alkyl or C 3-12  cycloalkyl; and m is 0 to 2.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 100.0
- Lexical Diversity: 1.58621
- Patent Class: 546.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14345922', '13819560', '13308287', '10420466', '12228421']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7854597431717381
- 35 USC 102 Novelty (BERT): 0.5170129583611135
- Combined Prediction Score: 0.7586150646906756
- Mean Citation Score: 286.6710240000001
- Max Citation Score: 328.88113
- Similarity Product: 245.89657185996293

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test